Valmark Advisers Inc. bought a new stake in MaxCyte, Inc. (NASDAQ:MXCT – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 83,927 shares of the company’s stock, valued at approximately $394,000. Valmark Advisers Inc. owned about 0.08% of MaxCyte […]
Stephens reaffirmed their overweight rating on shares of MaxCyte (NASDAQ:MXCT – Free Report) in a report published on Tuesday, Benzinga reports. The firm currently has a $11.00 price target on the stock. Several other equities analysts have also recently weighed in on the company. BTIG Research lowered their price target on MaxCyte from $10.00 to […]
MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) Director John Joseph Johnston sold 5,000 shares of MaxCyte stock in a transaction on Friday, January 26th. The shares were sold at an average price of $5.12, for a total transaction of $25,600.00. Following the completion of the sale, the director now owns 120,583 shares in the company, […]
MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $4.59, but opened at $4.98. MaxCyte shares last traded at $5.14, with a volume of 235,852 shares changing hands. Wall Street Analyst Weigh In Several research firms have recently issued reports on MXCT. Stephens […]
MaxCyte, Inc. (NASDAQ:MXCT – Free Report) – William Blair lifted their FY2023 EPS estimates for MaxCyte in a research note issued to investors on Tuesday, December 12th. William Blair analyst M. Larew now forecasts that the company will post earnings per share of ($0.41) for the year, up from their prior forecast of ($0.45). William […]